Viewing Study NCT05782361


Ignite Creation Date: 2025-12-24 @ 11:51 AM
Ignite Modification Date: 2025-12-31 @ 6:24 AM
Study NCT ID: NCT05782361
Status: RECRUITING
Last Update Posted: 2025-08-20
First Post: 2023-01-13
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
Sponsor: Institute of Cancer Research, United Kingdom
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module